| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | ACCELERON PHARMA INC | 400,000 | 10,588,000 | 1.97% | ||
| 52 | SPARK THERAPEUTICS INCORPORATED | 200,000 | 10,668,000 | 1.99% | ||
| 53 | BOSTON SCIENTIFIC CORP | 450,000 | 11,192,000 | 2.09% | ||
| 54 | ACADIA PHARMACEUTICALS INC COM | 350,000 | 12,033,000 | 2.24% | ||
| 55 | ZIMMER BIOMET HLDGS INC | 100,000 | 12,211,000 | 2.28% | ||
| 56 | SEATTLE GENETICS INC | 200,000 | 12,572,000 | 2.34% | ||
| 57 | BIOCRYST PHARMACEUTICALS | 1,500,000 | 12,600,000 | 2.35% | ||
| 58 | CLOVIS ONCOLOGY INC | 200,000 | 12,734,000 | 2.37% | ||
| 59 | NEUROCRINE BIOSCIE COM USD0.001 | 300,000 | 12,990,000 | 2.42% | ||
| 60 | AVEXIS INC COM | 175,000 | 13,305,000 | 2.48% | ||
| 61 | DBV TECHNOLOGIES S A | 500,000 | 17,610,000 | 3.28% | ||
| 62 | SPDR S&P 500 ETF TR | 100,000 | 23,574,000 | 4.39% | Put | |
| 63 | ISHARES TR | 250,000 | 34,370,000 | 6.41% | Put | |
| 64 | SPDR SER TR | 900,000 | 62,406,000 | 11.63% | Put |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001387131-17-002733, filed 2017.05.15).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
